Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis"
- PMID: 15572725
- DOI: 10.1001/jama.292.21.2655
Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis"
Comment in
-
Postmarketing surveillance--lack of vigilance, lack of trust.JAMA. 2004 Dec 1;292(21):2647-50. doi: 10.1001/jama.292.21.2647. Epub 2004 Nov 22. JAMA. 2004. PMID: 15572723 No abstract available.
Comment on
-
Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.JAMA. 2004 Dec 1;292(21):2622-31. doi: 10.1001/jama.292.21.2622. Epub 2004 Nov 22. JAMA. 2004. PMID: 15572720 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
